Circulating levels of IL-1B+IL-6 cause ER stress and dysfunction in islets from prediabetic male mice

Endocrinology

Volumn 154, Issue 9, 2013, Pages 3077-3088

  O'Neill, Christina M ^a,b   Lu, Christine ^a   Corbin, Kathryn L ^a   Sharma, Poonam R ^a   Dula, Stacey B ^a   Carter, Jeffrey D ^a   Ramadan, James W ^a,b   Xin, Wenjun ^b   Lee, Jae K ^b   Nunemaker, Craig S ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; CALCIUM; GLUCOSE; GLUCOSE REGULATED PROTEIN 78; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CELL FUNCTION; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; MALE; MOUSE; NONHUMAN; OSMOTIC PUMP; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL;

ANIMALS; ANIMALS, OUTBRED STRAINS; APOPTOSIS; CALCIUM SIGNALING; DRUG IMPLANTS; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; GLUCOSE; HUMANS; INFUSIONS, SUBCUTANEOUS; INSULIN; INTERLEUKIN-1BETA; INTERLEUKIN-6; ISLETS OF LANGERHANS; MALE; MICE; MICE, INBRED STRAINS; MICE, MUTANT STRAINS; PREDIABETIC STATE; RECOMBINANT PROTEINS; SPECIFIC PATHOGEN-FREE ORGANISMS; TISSUE CULTURE TECHNIQUES;

EID: 84883159268     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-2138     Document Type: Article

References (68)

1. Diabetes Genetics Initiative of Broad Institute of Harvard and MIT; Lund University; Novartis Institutes of BioMedical Research; Saxena R, Voight BF, Lyssenko V, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science. 2007;316:1331-1336.
2. Weir GC, Bonner-Weir S. Five stages of evolving β-cell dysfunction during progression to diabetes. Diabetes. 2004;53(Suppl 3):S16-S21.
3. Leahy JL, Hirsch IB, Peterson KA, Schneider D. Targeting β-cell function early in the course of therapy for type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010;95:4206-4216.
4. Roduit R, Morin J, Massé F, et al. Glucose down-regulates the expression of the peroxisome proliferator-activated receptor-α gene in the pancreatic β -cell. J Biol Chem. 2000;275:35799-35806.
5. Robertson RP, Harmon J, Tran PO, Poitout V. β-Cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes. 2004;53(Suppl 1):S119-S124.
6. Haataja L, Gurlo T, Huang CJ, Butler PC. Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocr Rev. 2008;29: 303-316.
7. Vozarova B, Weyer C, Lindsay RS, Pratley RE, Bogardus C, Tataranni PA. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002;51:455-461.
8. DonathMY,SchumannDM,FaulenbachM,Ellingsgaard H, Perren A, Ehses JA. Islet inflammation in type 2 diabetes: from metabolic stress to therapy. Diabetes Care. 2008;31(Suppl 2):S161-S164.
9. Eizirik DL, Cardozo AK, Cnop M. The role for endoplasmic reticulum stress in diabetes mellitus. Endocr Rev. 2008;29:42-61.
10. Gustafson B. Adipose tissue, inflammation and atherosclerosis. J Atheroscler Thromb. 2010;17:332-341.
11. Vandanmagsar B, Youm YH, Ravussin A, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med. 2011;17:179-188.
12. Kolb H, Mandrup-Poulsen T. The global diabetes epidemic as a consequence of lifestyle-induced low-grade inflammation. Diabetologia. 2010;53:10-20.
13. Cnop M, Welsh N, Jonas JC, Jorns A, Lenzen S, Eizirik DL. Mechanisms of pancreaticβ-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes. 2005;54(Suppl 2):S97-S107.
14. Eizirik DL, Colli ML, Ortis F. The role of inflammation in insulitis and β-cell loss in type 1 diabetes. Nat Rev Endocrinol. 2009;5:219-226.
15. Ehses JA, Perren A, Eppler E, et al. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes. 2007;56:2356-2370.
16. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327-334.
17. HuFB, Meigs JB, LiTY,Rifai N,MansonJE. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes. 2004; 53:693-700.
18. Spranger J, Kroke A, Möhlig M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population- based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes. 2003;52:812-817.
19. Alexandraki KI, Piperi C, Ziakas PD, et al. Cytokine secretion in long-standing diabetes mellitus type 1 and 2: associations with lowgrade systemic inflammation. J Clin Immunol. 2008;28:314-321.
20. O'Gorman MR, Donnenberg AD. Handbook of Human Immunology. Boca Raton, FL: CRC Press, Taylor & Francis Group; 2008.
21. Eizirik DL, Sandler S, Welsh N, et al. Cytokines suppress human islet function irrespective of their effects on nitric oxide generation. J Clin Invest. 1994;93:1968-1974.
22. Corbett JA, Sweetland MA, Wang JL, Lancaster JR Jr, McDaniel ML. Nitric oxide mediates cytokine-induced inhibition of insulin secretion by human islets of Langerhans. Proc Natl Acad Sci U S A. 1993;90:1731-1735.
23. Karlsen AE, Rønn SG, Lindberg K, et al. Suppressor of cytokine signaling 3 (SOCS-3) protects β -cells against interleukin-1β- and interferon-γ-mediated toxicity. Proc Natl Acad Sci U S A. 2001;98: 12191-12196.
24. Cardozo AK, Ortis F, Storling J, et al. Cytokines downregulate the sarcoendoplasmic reticulum pump Ca2 ATPase 2b and deplete endoplasmic reticulum Ca2+, leading to induction of endoplasmic reticulum stress in pancreatic β-cells. Diabetes. 2005;54:452-461.
25. 2+ sequestration in diabetic mouse islets of Langerhans. J Biol Chem. 1994;269:18279-18282.
26. RoeMW,Mertz RJ, Lancaster ME, Worley JF 3rd, Dukes ID. Thapsigargin inhibits the glucose-induced decrease of intracellular Ca2+ in mouse islets of Langerhans.AmJ Physiol. 1994;266:E852-E862.
27. Zhou YP, Teng D, Dralyuk F, et al. Apoptosis in insulin-secreting cells. Evidence for the role of intracellular Ca2- stores and arachidonic acid metabolism. J Clin Invest. 1998;101:1623-1632.
28. Shameli A, Yamanouchi J, Thiessen S, Santamaria P. Endoplasmic reticulum stress caused by overexpression of islet-specific glucose- 6-phosphatase catalytic subunit-related protein in pancreatic Betacells. Rev Diabet Stud. 2007;4:25-32.
29. Carter JD, Dula SB, Corbin KL, Wu R, Nunemaker CS. A practical guide to rodent islet isolation and assessment. Biol Proced Online. 2009;11:3-31.
30. Corbin KL, Hall TE, Haile R, Nunemaker CS. A novel fluorescence imaging approach for comparative measurements of pancreatic islet function in vitro. Islets. 2011;3:14-20.
31. Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem. 1985;260:3440-3450.
32. Dula SB, Jecmenica M, Wu R, et al. Evidence that low-grade systemic inflammation can induce islet dysfunction as measured by impaired calcium handling. Cell Calcium. 2010;48:133-142.
33. Lipson KL, Fonseca SG, Ishigaki S, et al. Regulation of insulin biosynthesis in pancreaticβ-cells by an endoplasmic reticulum-resident protein kinase IRE1. Cell Metab. 2006;4:245-254.
34. Cole BK, Keller SR, Wu R, Carter JD, Nadler JL, Nunemaker CS. Valsartan protects pancreatic islets and adipose tissue from the inflammatory and metabolic consequences of a high-fat diet in mice. Hypertension. 2010;55:715-721.
35. SpinasGA,Mandrup-Poulsen T, Molvig J, et al.Lowconcentrations of interleukin-1 stimulate and high concentrations inhibit insulin release from isolated rat islets of Langerhans. Acta Endocrinol (Copenh). 1986;113:551-558.
36. Palmer JP, Helqvist S, Spinas GA, et al. Interaction of β-cell activity and IL-1 concentration and exposure time in isolated rat islets of Langerhans. Diabetes. 1989;38:1211-1216.
37. Rutter GA, Tsuboi T, Ravier MA. Ca2- microdomains and the control of insulin secretion. Cell Calcium. 2006;40:539-551.
38. Oyadomari S, Takeda K, Takiguchi M, et al. Nitric oxide-induced apoptosis in pancreatic β-cells is mediated by the endoplasmic reticulum stress pathway. Proc Natl Acad Sci U S A. 2001;98:10845-10850.
39. Jahanshahi P, Wu R, Carter JD, Nunemaker CS. Evidence of diminished glucose stimulation and endoplasmic reticulum function in nonoscillatory pancreatic islets. Endocrinology. 2009;150:607-615.
40. Maedler K, Dharmadhikari G, Schumann DM, Størling J. Interleukin- 1β targeted therapy for type 2 diabetes. Expert Opin Biol Ther. 2009;9:1177-1188.
41. Dinarello CA, Donath MY, Mandrup-Poulsen T. Role of IL-1β in type 2 diabetes. Curr Opin Endocrinol Diabetes Obes. 2010;17: 314-321.
42. Kristiansen OP, Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes. 2005;54(Suppl 2): S114-S124.
43. Dunmore SJ, Brown JE. The role of adipokines in β-cell failure of type 2 diabetes. J Endocrinol. 2013;216:T37-T45.
44. Chang I, Cho N, Kim S, et al. Role of calcium in pancreatic islet cell death by IFN-γ/TNF-α. J Immunol. 2004;172:7008-7014.
45. Zawalich WS, Zawalich KC, Rasmussen H. Interleukin-1β exerts glucose-dependent stimulatory and inhibitory effects on islet cell phosphoinositide hydrolysis and insulin secretion. Endocrinology. 1989;124:2350-2357.
46. Maedler K, Sergeev P, Ris F,et al. Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets. J Clin Invest. 2002;110:851-860.
47. Masters SL, Dunne A, Subramanian SL, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol. 2010;11:897-904.
48. Satin LS. Localized calcium influx in pancreatic β-cells: its significance for Ca2+-dependent insulin secretion from the islets of Langerhans. Endocrine. 2000;13:251-262.
49. Mears D. Regulation of insulin secretion in islets of Langerhans by Ca2+ channels. J Membr Biol. 2004;200:57-66.
50. Wiederkehr A, Wollheim CB. Impact of mitochondrial calcium on the coupling of metabolism to insulin secretion in the pancreatic β-cell. Cell Calcium. 2008;44:64-76.
51. Levy J. Abnormal cell calcium homeostasis in type 2 diabetes mellitus: a new look on old disease. Endocrine. 1999;10:1-6.
52. Chandra J, Zhivotovsky B, Zaitsev S, Juntti-Berggren L, Berggren PO, Orrenius S. Role of apoptosis in pancreatic β-cell death in diabetes. Diabetes. 2001;50(Suppl 1):S44-S47.
53. Ramadan JW, Steiner SR, O'Neill CM, Nunemaker CS. The central role of calcium in the effects of cytokines on β-cell function: implications for type 1 and type 2 diabetes. Cell Calcium. 2011;50:481-490.
54. Allagnat F, Fukaya M, Nogueira TC, et al. C/EBP homologous protein contributes to cytokine-induced pro-inflammatory responses and apoptosis in β-cells. Cell Death Differ. 2012;19:1836-1846.
55. Grunnet LG, Aikin R, Tonnesen MF, et al. Proinflammatory cytokines activate the intrinsic apoptotic pathway in β-cells. Diabetes. 2009;58:1807-1815.
56. Barbu A, Welsh N, Saldeen J. Cytokine-induced apoptosis and necrosis are preceded by disruption of the mitochondrial membrane potential (Δψ m) in pancreatic RINm5F cells: prevention by Bcl-2. Mol Cell Endocrinol. 2002;190:75-82.
57. Luciani DS, Gwiazda KS, Yang TL, et al. Roles of IP3R and RyR Ca2+ channels in endoplasmic reticulum stress and β-cells death. Diabetes. 2009;58:422-432.
58. Maedler K, Størling J, Sturis J, et al. Glucose- and interleukin-1β- induced β-cells apoptosis requires Ca2- influx and extracellular signal- regulated kinase (ERK) 1/2 activation and is prevented by a sulfonylurea receptor 1/inwardly rectifying K- channel 6.2 (SUR/ Kir6.2) selective potassium channel opener in human islets. Diabetes. 2004;53:1706-1713.
59. Fei H,ZhaoB,ZhaoS,WangQ. Requirements of calcium fluxes and ERK kinase activation for glucose- and interleukin-1β-induced β-cells apoptosis. Mol Cell Biochem. 2008;315:75-84.
60. Sauter NS, Schulthess FT, Galasso R, Castellani LW, Maedler K. The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia. Endocrinology. 2008;149:2208-2218.
61. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007;356: 1517-1526.
62. Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science. 2001;293:1673-1677.
63. Goldfine AB, Silver R, Aldhahi W, et al. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci. 2008;1:36-43.
64. Eizirik DL, Bendtzen K, Sandler S. Short exposure of rat pancreatic islets to interleukin-1β induces a sustained but reversible impairment in β-cells function: influence of protease activation, gene transcription, and protein synthesis. Endocrinology. 1991;128:1611-1616.
65. Hughes KJ, Chambers KT, Meares GP, Corbett JA. Nitric oxides mediates a shift from early necrosis to late apoptosis in cytokinetreated β-cells that is associated with irreversible DNA damage. Am J Physiol Endocrinol Metab. 2009;297:E1187-E1196.
66. Derdemezis CS, Voulgari PV, Drosos AA, Kiortsis DN. Obesity, adipose tissue and rheumatoid arthritis: coincidence or more complex relationship? Clin Exp Rheumatol. 2011;29:712-727.
67. Farah CS, Salome CM. Asthma and obesity: a known association but unknown mechanism. Respirology. 2012;17:412-421.
68. Sethi G, Shanmugam MK, Ramachandran L, Kumar AP, Tergaonkar V. Multifaceted link between cancer and inflammation. Biosci Rep. 2012;32:1-15.